Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE TriReme Medical, LLC
Interim Outcomes in CHOCOLATE BAR Registry Demonstrate High Rates of Procedural Success and Limb Preservation
PLEASANTON, Calif. and SINGAPORE, Feb. 6, 2014 /PRNewswire/ -- Interim results from The CHOCOLATE® BAR Registry conducted in the US demonstrate that use of the CHOCOLATE® PTA balloon achieved high rates of treatment success and limb preservation in patients with peripheral arterial disease. The results from the first 350 patients enrolled and treated were presented by Dr. Tony Das (Cardiovascular Research Institute, Dallas, TX) at the Leipzig Interventional Course, LINC 2014.
CHOCOLATE® BAR is a prospective, core lab adjudicated registry conducted at 33 clinical centers in the US. A broad range of patients with advanced atherosclerotic disease in their legs were treated in this trial including patients with high risk of amputation (Rutherford 5 and 6, total occlusions, long and calcified lesions). The study included two distinct patient groups: those with atherosclerotic disease mainly in above-the-knee vessels (ATK) or below-the-knee vessels (BTK). Dr. Das reported the protocol mandated three month and six month follow up respectively.
The highlights of the interim data presented included:
Dr. Jihad Mustapha (Metro Hospital, Wyoming, MI), Principal Investigator for the Trial, commented, "In this all-comers registry comprised of a large number of patients with diabetes and some of the most complex lesions including chronic total occlusions and high degrees of calcium, these results with CHOCOLATE® are remarkable. CHOCOLATE® is an attractive alternative to conventional therapies that often have poor outcomes."
"CHOCOLATE® allows me the confidence to achieve a larger lumen without the concern that I might dissect the vessel and have to leave behind a permanent implant such as a stent," added Dr. Andrej Schmidt (Park Hospital, Leipzig, Germany) who successfully used CHOCOLATE® during a live case transmission at the LINC 2014 conference.
"We are delighted with the outcomes presented," announced Dr. Eitan Konstantino, President and CEO of TriReme Medical. "This study enrolled patients with significantly more advanced disease than most other studies and yet our clinical outcomes are competitive with currently available advanced therapies, including first generation drug-coated balloons."
About TriReme Medical, LLC
TriReme, a subsidiary of Singapore based QT Vascular Ltd., is an emerging leader in the development and commercialization of next generation minimally invasive devices for the treatment of complex arterial disease. The company is focused on the US and the emerging Asian markets.
©2012 PR Newswire. All Rights Reserved.